Drug Topics E-News:
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Modern Medicine Network
Resource Centers
CME/CE
Medical Economics
Careers
Community
Clinical Tools
  Drug Topics E-News
 
SEPTEMBER 15, 2009
IN THIS ISSUE
• Pharms hurt by mail order
• FDA OKs Cervarix
• New PharmD program offered
• Pro-life pharms get injunction
  TOP SEARCHES: CE // Diabetes // Asthma

Ohio community pharmacists say mail order policies hurt
Some school districts in Ohio are creating policies that force employees to get prescriptions from mail order programs — a move pharmacists say is costing them business. click here.

FDA advisory committee recommends Cervarix
GlaxoSmithKline has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the Food and Drug Administration (FDA) voted that clinical data support the efficacy and safety of Cervarix, the company’s cervical cancer vaccine candidate. More...

University of Missouri-Kansas to offer pharmacy doctorate program
The University of Missouri-Kansas City (UMKC) and Missouri State University (MSU) in Springfield, Mo., have entered into an agreement that will allow students on the Springfield campus to earn a Doctor of Pharmacy degree from UMKC. More...

Pro-life pharmacists win preliminary injunction
Two Illinois pharmacy owners have gained a temporary victory in their effort to conduct their practice according to their pro-life opinions. More...


Key Topic Updates
Issues & Trends
 
Professional
 
Clinical
 
Technology
 
Regulatory & Law

Key Topic Updates

Survey

What role do therapeutic substitutions play in your career?

How often do you implement therapeutic substitution?

<20% of prescriptions

  

55%

21 to 50% of prescriptions

  

17%

51 to 75% of prescriptions

  

13%

>75% of prescriptions

  

14%

This month we would like to know...

How much input do you have into retail business decisions at your pharmacy?

A) A lot
B) Some
C) None

Click here to vote

Contact Us
Click here to learn more about the Drug Topics editorial team.

Click here to contact the Drug Topics editorial team.

Click here to contact the Drug Topics sales team.

Click here to learn about direct mail, reprints and classifieds in Drug Topics.

Drug Topics Digital Edition
Click here to to view the most recent issue.

Click here to subscribe.

Follow us on Twitter.

Share Drug Topics E-News with a friend

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.

To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.